Trial Profile
A five-arm, randomized, double-blind, placebo- and active-controlled, and parallel study to evaluate the cardiac safety of rasagiline in patients with Parkinson' disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary) ; Moxifloxacin
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms TQT Study
- 09 Nov 2015 New trial record